Abstract: Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria.

Abstract: The invention relates to 17?-(5-hydroxy-C5-hydrocarbyl)-1,3,5(10)-estratrien-3,17?-diol derivatives having cicatrising activity, preferably for topical use on wounds, without significant systemic effects, and to pharmaceutical compositions containing them. In particular, the invention relates to estradiol 17?-(5-hydroxypentyn-1-yl)derivatives and 3-esters, 5?-esters and 3,5?-diesters thereof and to a process for the preparation thereof by reaction of 3-OR-protected estrone with an alkali metal derivative of OR-protected 5-pentynol, followed by 3-, 5-? or 3,5?-esterifÊcation.

Abstract: The present invention concerns an enantiomer R of a compound of Formula (I), wherein X is —NH—R1 or of Formula (V) or (VI), R1 is —(CH2)n—R2, R2 is a linear, branched or cyclic C1C6 aliphatic group, —O—(CH2)n—CH3, —NH—CO—(CH2)n—CH3, a 5- or 6-membered aliphatic or aromatic ring optionally comprising a heteroatom, a 5- or 6-membered aromatic ring substituted by one or two substituents, said substituents being selected from the group consisting of —OH, —O(alkyl C1C3) and —OCO(alkyl C1C3), or of Formula (V), R3 is H or a C1-C3 aliphatic group and R4 is a linear C1-C3 or a branched C3-C12 aliphatic group, or R3 is a C1-C3 aliphatic group and R4 is a linear C1-C12 aliphatic group, Y is O, CH—(CH2)n—CH3 or N(CO)(CH2)n—CH3, and n is an integer from O to 6.

Abstract: New compounds belonging to the structural formula (I) are described. in which R1, R2, A, Y and X are specified in the description, useful in the treatment of cholestasis and substantially devoid of antibacterial activity. The synthesis process of said compounds, the pharmaceutical compositions containing them and their use in therapy are also described.

Abstract: The invention relates to 17?-(5-hydroxy-C5-hydrocarbyl)-1,3,5(10)-estratrien-3,17?-diol derivatives having cicatrising activity, preferably for topical use on wounds, without significant systemic effects, and to pharmaceutical compositions containing them. In particular, the invention relates to estradiol 17?-(5-hydroxypentyn-1-yl)derivatives and 3-esters, 5?-esters and 3,5?-diesters thereof and to a process for the preparation thereof by reaction of 3-OR-protected estrone with an alkali metal derivative of OR-protected 5-pentynol, followed by 3-, 5-? or 3,5?-esterification.

Abstract: A compound having general formula (I) wherein R1, R2, R′3, R4, and R6 have the meanings stated in the description, acid addition salts thereof with pharmaceutically acceptable organic and inorganic acids an pharmaceutically acceptable quaternary salts thereof.

Abstract: A therapeutic method comprising treating a patient suffering from a neurodegenerative disease with a therapeutically effective quantity of a p-aminophenol derivative.

Abstract: Phenylcarbamate derivatives suitable to the use as anticholinesterase substances having the general formula (I) ##STR1## wherein the meaning of R.sub.1 -R.sub.7 and X substituentes together with n will be defined in the text.

Abstract: Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase activity inhibitors, having general formula (I) ##STR1## where R stands for an amine selected out of the group consisting of ##STR2## and n, R1, R2, R3, and R4 are as defined in the text.

Abstract: Thiadiazole derivatives of general formula (I) ##STR1## wherein R.sub.1 is selected from the class consisting of: C.sub.1 -C.sub.10 linear or branched alkyl, benzyl, optionally substituted at the aromatic ring with one or more groups selected on their turn from the class consisting of : C.sub.1 -C.sub.20 linear or branched alkyl residues , nitro groups, halogen atoms, C.sub.1 -C.sub.20 linear or branched alkoxy, hydroxy and C.sub.2 -C.sub.20 linear or branched acyloxy groups, R.sub.2 is selected from H, C.sub.2 -C.sub.10 alkanoyl, cycloalkanoyl wherein this ring has from 3 to 10 carbon atoms, aroyl, and R.sub.3 is selected from H and C.sub.1 -C.sub.10 alkyl, for the treatment of depressive states and anxiety, a process for their preparation and relative pharmaceutical compositions containing them as the active ingredient.

Abstract: There are described 8-(1-aminocycloalkyl)-1,3-dialckylxantaine, their derivatives and their salts with adenosine antagonist activity. A process for the preparation of said compounds and pharmaceutical compositions containing them as antidepressant, nootropic and psychostimolant drugs are also described.

Abstract: Phosphatidylinositol analogues, inhibitors of phosphatidylinositol-specific phospholipase C of general formula (I) ##STR1## wherein X and R have the meanings specified in the description, suitable for preparing pharmaceutical compositions for the treatment of tumoral, thrombotic and inflammatory type pathologies.

Abstract: Physostigmine derivatives with acetylcholinesterase inhibition properties, of general formula: ##STR1## in which R is a linear alkyl of from 2 to 20 C. atoms, a branched alkyl, a cycloalkyl or an aryl, when R' is H, or R and R' are linear alkyl of from 2 to 20 C. atoms.

Abstract: Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase activity inhibitors, having general formula (I) ##STR1## where R stands for an amine selected out of the group consisting of ##STR2## and n, R1, R2, R3, and R4 are as defined in the text.

Abstract: Compounds related to acetazolamide and to its N-methyl derivatives, of the formula: ##STR1## wherein Y is one of the following groups: ##STR2## R.sub.1 being a straight or branched alkylene or arylalkylene, or a phenylene, and the processes for their preparation; the compounds so obtained are inhibitors of carbonic anhydrase like acetazolamide but, in addition, they are well absorbed topically so that they can be used as drugs for treating glaucoma.

Abstract: Phosphatidylinositol of high purity useful for the treatment of central nervous system disorders, prepared from vegetal substances containing it by treating them with reagents suitable for the functionalization of the inositol hydroxy group with protective groups, separating the thus protected phosphatidylinositol by solvent extraction or chromatography, and finally removing said protective groups under conditions which do not modify the phosphatidyl group.

Abstract: The herein-described invention concerns new 2,3-dihydro-5-oxy-4,6,7-trimethylbenzofuranes 2-(RS)-substituted, the synthesis procedure and the relative therapeutic use as antioxidizing and radical-scavenging pharmaceuticals with mucoregulation and anti-ischemic properties.

Abstract: The present invention relates to (RS)-2-(2,3-dihydro-5-hydroxy-4-,6-trimethylbenozfuranyl) acetic acids and 2-(2,3-dihydro-5-acyloxy-4-,6,7-trimethylbenzofuranyl) acetic acids and esters thereof, the process for producing them and their relevant therapeutical use as mucoregulators and antio-ischemic agents.

Abstract: Compounds related to acetazolamide and to its N-methyl derivatives, of the formulae: ##STR1## wherein Y is one of the following groups: ##STR2## R.sub.1 being a straight or branched alkylene or arylalkylene, or a phenylene, and the processes for their preparation; the compounds so obtained are inhibitors of carbonic anhydrase like acetazolamide but, in addition, they are well absorbed topically so that they can be used as drugs for treating glaucoma.

Abstract: The present invention relates to (RS)-2-(2,3-dihydro-5-hydroxy-4,6,7-trimethylbenzofuranyl) acetic acids and 2-(2,3-dihydro-5-acyloxy-4,6,7-trimethylbenzofuranyl) acetic acids and esters thereof, the process for producing them and their relevant therapeutical use as mucoregulators and antiischemic agents.